Skip links

About Us

Setting a new standard in precision oncology with our next-generation copper-based radiopharmaceuticals

Our Vision

NUCLIDIUM’s vision is to address the unmet need in cancer medicine by providing personalised treatment options for cancer patients at every stage of their disease to improve long-term survival. Our therapeutic approach combines accurate diagnosis and staging of cancers at an early stage with a highly personalized treatment dose enabling less aggressive treatment and a significantly better quality of life for the patient.

We Aim to Address the Persistent Unmet Need in Oncology

Our therapeutic portfolio includes personalised treatment strategies for key solid tumour indications with high need for innovation. 

Meet our Team

TEAM

Our Diverse and Dynamic Team

Dr. Leila Jaafar-Thiel

CEO and Founder
Andreas Schuh

Andreas Schuh

CFO/COO
Ben Pais (MD)

Ben Pais (MD)

CMO
Prof. Dr. Gustav von Schulthess (MD, PhD)

Prof. Dr. Gustav von Schulthess (MD, PhD)

Medical Advisor & Co-Founder
Dr. Francesco de Rose

Dr. Francesco de Rose

Head of Pharmaceutical Development
Dr. Markus Baier

Dr. Markus Baier

Head of Technical Project Development
Dr. Sebastian Schleser

Dr. Sebastian Schleser

Head of Chemistry

Ann-Kristin Gabriel

Office & Financial Manager

Dr. Nicole Schubert

Head of Quality

Dr. Sascha Frölich

Technical Project Leader
Sophie Kurzbach

Sophie Kurzbach

Technical Project Lead
Thorsten Michael

Thorsten Michael

Head of Clinical Operations
Hakan Kalfa

Hakan Kalfa

Chemist
Adriano Bolognani

Adriano Bolognani

PhD Student

Valeria Colón Oliveros

Working Student

Sara Maria Trujillo Garcia

Working Student

Eleni Andreadaki

Working Student

Board of Directors

Tony Rosenberg

Chairman

Dr. Leila Jaafar-Thiel

CEO & Founder

Regina Hodits, PhD

Managing Director at Angelini Ventures

David Meek

Independent Director

Liliana Nordbakk

Partner Life Sciences at Neva SGR

Daniel Parera, MD

Partner at Kurma Partners

Scientific Advisors

Bela Denes, MD

Prof. Dr. Melpomeni Fani

Dr. Michael L. Nickels

Oliver Sartor, MD

Dr. Gary Ulaner (MD, FACNM, PhD)

Prof. Dr. Dr. Damian Wild

Investors

Our Investors

NUCLIDIUM is supported by leading European biotech investors on its mission of setting a new standard in precision oncology

Our Partners

NUCLIDIUM collaborates actively with leading partners in a multitude of interdisciplinary fields – to optimise our production processes, further expand our supply network and advance our innovative product portfolio into the clinic. Join our global network of collaborators to set a new standard in precision oncology providing a true benefit to cancer patients worldwide. For more information, contact us at info@nuclidium.com.

Explore
Drag